PACIRA BIOSCIENCES, INC.

NASDAQ: PCRX (Pacira BioSciences, Inc.)

Kemas kini terakhir: 04 Jul, 9:54AM

23.22

0.01 (0.04%)

Penutupan Terdahulu 23.21
Buka 23.30
Jumlah Dagangan 202,316
Purata Dagangan (3B) 817,124
Modal Pasaran 1,075,195,136
Harga / Pendapatan (P/E Ke hadapan) 8.06
Harga / Jualan (P/S) 1.53
Harga / Buku (P/B) 1.35
Julat 52 Minggu
11.16 (-51%) — 27.64 (19%)
Tarikh Pendapatan 28 Jul 2025 - 1 Aug 2025
Margin Keuntungan -14.76%
Margin Operasi (TTM) 4.63%
EPS Cair (TTM) -2.24
Pertumbuhan Hasil Suku Tahunan (YOY) 1.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -46.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 79.70%
Nisbah Semasa (MRQ) 2.41
Aliran Tunai Operasi (OCF TTM) 175.75 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 144.75 M
Pulangan Atas Aset (ROA TTM) 3.56%
Pulangan Atas Ekuiti (ROE TTM) -12.27%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Pacira BioSciences, Inc. Menaik Menaik

AISkor Stockmoo

0.6
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 3.5
Osilator Teknikal -0.5
Purata 0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PCRX 1 B - - 1.35
RGC 10 B - - 1.07
BGM 2 B - - 46.23
INDV 2 B - - 145.25
ANIP 1 B - - 3.37
COLL 1 B - 26.32 4.36

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 1.79%
% Dimiliki oleh Institusi 111.09%

Pemilikan

Nama Tarikh Syer Dipegang
Doma Perpetual Capital Management Llc 31 Mar 2025 1,804,069
101.45101.4579.1079.1056.7556.7534.4034.4012.0512.05Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
11.16 (-51%) — 27.64 (19%)
Median 30.00 (29.20%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Needham 09 May 2025 30.00 (29.20%) Beli 25.12

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
24 Jul 2025 Pengumuman Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
22 Jul 2025 Pengumuman Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
03 Jul 2025 Pengumuman Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Jun 2025 Pengumuman Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
11 Jun 2025 Pengumuman Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
05 Jun 2025 Pengumuman Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 May 2025 Pengumuman Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
14 May 2025 Pengumuman Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
08 May 2025 Pengumuman Pacira BioSciences Reports First Quarter 2025 Financial Results
06 May 2025 Pengumuman Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
02 May 2025 Pengumuman Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
29 Apr 2025 Pengumuman Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
28 Apr 2025 Pengumuman Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
Papar semua
24.1024.1023.4223.4222.7422.7422.0622.0621.3821.38Jul 3Jul 3Jul 7Jul 7Jul 8Jul 8Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.200-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda